


PHARMACEUTICAL 2022



Reneo Pharmaceuticals Inc. Rank 144 of 475





PHARMACEUTICAL 2022



Reneo Pharmaceuticals Inc. Rank 144 of 475

The relative strengths and weaknesses of Reneo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Reneo Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 251% points. The greatest weakness of Reneo Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.66%, being 277% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	153,734
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,202
Liabilities, Non-Current	0
Other Assets	78
Other Compr. Net Income	34
Other Expenses	0
Other Liabilities	611
Other Net Income	0
Property and Equipment	212
Research and Development	28,169
Revenues	48
Selling, General and Administrative Expense	11,649

Output Variable	Value in 1000 USD
Assets	154,024
Liabilities	6,813
Expenses	39,818
Stockholders Equity	147,211
Net Income	-39,770
Comprehensive Net Income	-39,753
Economic Capital Ratio	0.67%